Wockhardt Limited has informed the Exchange regarding a press release dated January 31, 2025, titled Wockhardt s Zaynich? (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in a global, pivotal, registration-enabling Phase III study in complicated urinary tract infection (cUTI) achieving 96.8% clinical cure rate ".